R&D Network
Our pipeline forms a robust portfolio of investigational
therapies in varied stages of clinical development.

R&D Network

Hanmi R&D network consists of 6 sites creating a synergistic effect. Fully integrated 3 R&D Centers in Dongtan (Korea), Paltan (Korea), and Beijing (China) focus on new drug discovery and formulation research. Global Business Division and New Product Development Division in our headquarters performs clinical research, regulatory affairs and licensing business. In addition, there are two process development research sites for biologics and chemical APIs.

R&D Network Table
NAME Location Major Fields of Research Number of Personnel
Hanmi R&D Center Dongtan, Gyeonggi-do in Korea New biological drugs, New chemical drugs 150+
Global Business Division and New Product Development Division (Headquarters) Songpa-gu, Seoul in Korea Clinical studies, Regulatory affairs, Licensing in & out 110+
Pharmaceutical R&D Team Paltan, Gyeonggi-do in Korea New medicines, Drug transfer platform technology 60+
Bioprocess Development Team Pyeongtaek, Gyeonggi-do in Korea Manufacturing and development of recombinant protein products 50+
Hanmi Fine Chemical R&D Center Sihwa, Gyeonggi-do in Korea Mass production of active pharmaceutical ingredients 50+
Beijing Hanmi R&D Center Beijing in China New bispecific antibodies 120+